Advertisement
UK markets close in 2 hours 46 minutes
  • FTSE 100

    8,100.86
    +60.48 (+0.75%)
     
  • FTSE 250

    19,736.43
    +17.06 (+0.09%)
     
  • AIM

    755.79
    +1.10 (+0.15%)
     
  • GBP/EUR

    1.1669
    +0.0025 (+0.21%)
     
  • GBP/USD

    1.2478
    +0.0016 (+0.13%)
     
  • Bitcoin GBP

    51,055.36
    -2,282.28 (-4.28%)
     
  • CMC Crypto 200

    1,361.83
    -20.74 (-1.50%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    83.18
    +0.37 (+0.45%)
     
  • GOLD FUTURES

    2,336.80
    -1.60 (-0.07%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,999.57
    -89.13 (-0.49%)
     
  • CAC 40

    8,023.11
    -68.75 (-0.85%)
     

Valeant’s U.S. Diversified Products Segment in 4Q17 and 2017

Valeant’s U.S. Diversified Products Segment in 4Q17 and 2017

In 4Q17, Valeant Pharmaceuticals International’s (VRX) U.S Diversified Products generated revenues of $335 million compared to $398 million in 4Q16, a 16% decline on a YoY (year-over-year) basis.